Anti-Infectious Human Vaccination in Historical Perspective

References

• André FE, Booy R, Bock HL, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull WHO 2008;86:81–160.
   Web of Science ®Google Scholar
• Anon. Impact of vaccines universally recommended for children. 1900–1998. MMWR 1999;48:243–248.
   PubMedGoogle Scholar
• Paran N, Sutter G. Smallpox vaccines. New formulations and revised strategies for vaccination. Hum Vaccin 2009;5:824–831.
   PubMed Web of Science ®Google Scholar
• Henderson DA, Klepac P. Lessons from the eradication of smallpox: an interview with D. A. Henderson. Philos Trans R Soc Lond B Biol Sci 2013;368:20130113.
   PubMed Web of Science ®Google Scholar
• Chia WN, Goh YS, Rénia L. Novel approaches to identify protective malaria vaccine candidates. Front Microbiol. 2014 Nov 17;5:586.
   PubMed Web of Science ®Google Scholar
• Karp CL, Wilson CB, Stuart LM. Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool. Immunol Rev. 2015;264:363–381.
   PubMed Web of Science ®Google Scholar
• John M, Gaudieri S. Influence of HIV and HCV on T cell antigen presentation and challenges in the development of vaccines. Front Microbiol. 2014;5:514.
   PubMed Web of Science ®Google Scholar
• Dunning R. Some observations on vaccination or the inoculated Cow-Pox. London: March and Teape; 1800. p. 5.
   Google Scholar
• Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. Embo Mol Med 2014;pii:emmm.201403876v1. doi:10.1002/emmm.201403876
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Med 2011;12:509–517.
   Web of Science ®Google Scholar
• Jenner E. An enquiry into the causes and effects of variolae vaccinae a disease discovered in some western countries of England, particularly Gloucestershire, and known by the name of Cow Pox. London: printed for the author by Sampson Low; 1798.
   Google Scholar
• Cha SH. The history of vaccination and current vaccination policies in Korea. Clin Exp Vaccine Res 2012;1:3–8.
   PubMedGoogle Scholar
• Baxby D. Edward Jenner's role in the introduction of smallpox vaccine. In: Stanley Plotkin, editor. History of vaccine development. New York: Springer Science+Business Media, LLC; 2011. pp. 13–19
   Google Scholar
• Behbehani AM. The smallpox story: life and death of an old disease. Microbiol Rev 1983;47:455–509.
   PubMedGoogle Scholar
• Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 2005;18:21–5.
   PubMedGoogle Scholar
• Grabenstein JD, Pittman PR, Greenwood JT, et al. Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol Rev. 2006;28:3–26.
   PubMed Web of Science ®Google Scholar
• Rotz LD, Khan AS, Lillibridge SR, et al. Public health assessment of potential biological terrorism agents. Emerg Infect Dis. 2002;8:225–230.
   PubMed Web of Science ®Google Scholar
• Artenstein AW, Grabenstein JD. Smallpox vaccines for biodefense: need and visibility. Expert Rev. Vaccines 2008;7:1225–1237.
   PubMed Web of Science ®Google Scholar
• Berche P. Louis Pasteur: from crystals of life to vaccination. Clin Microbiol Infect 2012;18(Suppl.5):1–6.
   PubMed Web of Science ®Google Scholar
• Pasteur L. Sur les maladies virulentes et en particulier sur la maladie appelée vulgairement choléra des poules. CR Acad Sci (Paris) 1880; 90:239–248.
   Google Scholar
• Pasteur L. De l'atténuation du virus du cholera des poules. CR Acad Sci (Paris) 1880; 91:673–80.
   Google Scholar
• Pasteur L, Chamberland CE. Sur la vaccination charbonneuse. CR Acad Sci (Paris) 1881;92:1378–1383.
   Google Scholar
• Kaur M, Singh S, Bhatnagar R. Anthrax vaccines: present status and future prospects. Expert Rev Vaccines. 2013;12:955–970.
   PubMed Web of Science ®Google Scholar
• Pasteur L. Méthode pour prévenir la rage aprés morsure. C R Acad Sci (Paris) 1885;101:765–774.
   Google Scholar
• Succi RC, Farhat CK. Vaccination in special situations. J Pediatr (Rio J) 2006;82:S91–100.
   PubMedGoogle Scholar
• Salmon DE, Smith T. On a new method of producing immunity from infectious diseases. Am Vet Rev 1886;10:63–69.
   Google Scholar
• Pfeiffer R, Kolle W. Experimental investigation of prevention of typhoid fever in man by immunization. Dtsch. Med. Wochenschr 1896;22:735–737.
   Google Scholar
• Wright AE, On the results which have been obtained by anti-typhoid inoculation. Lancet 1902;2:651–654.
   Google Scholar
• Bornside GH. Waldemar Haffkine's cholera vaccines and the Ferran–Haffkine priority dispute. J Hist Med All Sci 1982;37:399–422.
   PubMed Web of Science ®Google Scholar
• Haffkine WM. Remarks on the plague prophylactic fluid. Br Med J 1897;1:1461–1462.
   Google Scholar
• Plotkin SA. Vaccines: past, present and future. Nat Med Suppl 2005;11:S5-S11.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Demicheli V, Pratt M. Vaccines for preventing plague. Cochrane Database Syst Rev 2000;(2):CD000976.
   Google Scholar
• Williamson ED, Oyston PCF. Protecting against plague: towards a next-generation vaccine. Clin Exp Immunol 2012;172:1–8.
   Web of Science ®Google Scholar
• Tuells J. Vaccinology: the name, the concept, the adjectives. Vaccine 2012;30:5491–5495.
   PubMed Web of Science ®Google Scholar
• Tan SY, Kwok E. Albert calmette (1863–1933): originator of the BCG vaccine. Singapore Med J 2012;53:433–434.
   PubMed Web of Science ®Google Scholar
• Koch R. The current state of the struggle against tuberculosis. Nobel lecture December 12 1905. From nobel lectures. Physiology or Medicine 1901–1921. Amsterdam: Elsevier Publishing Company; 1967.
   Google Scholar
• Calmette A, Guérin C, Breton M. Contribution a l’étude de la tuberculose expérimental du cobaye (infection et essays de vaccination par la voie digestive). Ann Inst Pasteur Paris 1907;21: 401–416.
   Google Scholar
• Luca S, Mihaescu T. History of BCG Vaccine. MAEDICA J Clin Med 2013;8:53–58.
   Google Scholar
• Clemens JD. The BCG controversy: a methodological and statistical reappraisal. JAMA 1983;249:2362–2369.
   PubMed Web of Science ®Google Scholar
• Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58:470–480.
   PubMed Web of Science ®Google Scholar
• Bourdin Trunz B, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006;367:1173–1180.
   PubMed Web of Science ®Google Scholar
• Rodrigues LC, Mangtani P, Abubakar I. How does the level of BCG vaccine protection against tuberculosis fall over time? BMJ 2011;343:d5974.
   PubMed Web of Science ®Google Scholar
• Jensen K, Ranganathan UD, Van Rompay KK, et al. A recombinant attenuated Mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaques. Clin Vaccine Immunol. 2012;19:1170–1181.
   PubMed Web of Science ®Google Scholar
• Hesseling AC, Johnson LF, Jaspan H, et al. Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants. Bull. World Health Organ. 2009;87:505–511.
   PubMed Web of Science ®Google Scholar
• Roth AE, Stensballe LG, Garly ML, et al. Beneficial non-targeted effects of BCG: ethical implications for the coming introduction of new TB vaccines. Tuberculosis 2006;86:397–403.
   PubMed Web of Science ®Google Scholar
• Ritz N, Mui M, Balloch A, et al. Nonspecific effect of Bacille Calmette–Guérin vaccine on routine immunisations. Vaccine 2013;31:3098–3103.
   PubMed Web of Science ®Google Scholar
• World Health Organization—Tuberculosis: a global emergency. Geneva, Switzerland: WHO; 1994.
   Google Scholar
• Lawn SD, Zumla AI Diagnosis of extrapulmonary tuberculosis using the Xpert((R)) MTB/RIF assay. Expert Rev Anti-Infect Ther 2012;10:631–635.
   PubMed Web of Science ®Google Scholar
• Theiler M, Smith HH. The use of yellow fever virus by in vitro cultivation for human immunization. J Exp Med 1937;65;787–800.
   PubMedGoogle Scholar
• Frierson JG. The Yellow Fever Vaccine: a History. Yale J Biol Med 2010;83:77–85.
   PubMedGoogle Scholar
• Sellards W, Mathis C, Laigret J. Sensibilité du Macacus rhesus au virus de la fièvre jaune. CR Acad Sci. 1928;186:604–606.
   Google Scholar
• Theiler M, Smith HH. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Exp Med. 1937;65:767–786.
   PubMedGoogle Scholar
• Monath TP. Yellow fever vaccines: the success of empiricism, pitfalls of application, and transition to molecular vaccinology. In: Plotkin SA, editor, History of vaccine development. New York: Springer; 2011. p. 119.
   Google Scholar
• Available at http://www.who.int/vaccines/en/yellowfever.shtml.
   Google Scholar
• Querec T, Bennouna S, Alkan S, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med. 2006;203: 413–424.
   PubMed Web of Science ®Google Scholar
• Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009; 10:116–125.
   PubMed Web of Science ®Google Scholar
• Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008;205:3119–3131.
   PubMed Web of Science ®Google Scholar
• Roux E, Yersin A. Contribution à l’étude de la diphtérie. Ann Inst Pasteur 1888;2:421–499.
   Google Scholar
• Faber K. Die Pathogenie des Tetanus. Berl Klin Woch 1890;27:717–720.
   Google Scholar
• Linton DS. Emil Von Behring. Infectious Diseases, Immunology, Serum Therapy. Philadelphia: American Philosophical Society; 2005.
   Google Scholar
• Ramon G. Sur le pouvoir floculant et sur le proprietés immunisantes d'une toxine diphterique rendu anatoxic (anatoxine). CR Acad Sci (Paris) 1923;177:1338–1340.
   Google Scholar
• Ramon G, Zeller C. De la valeur antigenique de l'anatoxine tétanique chez l'homme. CR Acad Sci (Paris) 1926;182:245–247.
   Google Scholar
• Smith LA. Botulism and vaccines for its prevention. Vaccine 2009;27:D33–D39.
   PubMed Web of Science ®Google Scholar
• Meyer AH, Kristensen M, Sörensen E. Whooping-Cough vaccination. Acta paediat. 1924;4:21.
   Google Scholar
• Anon. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010;85:385–400.
   PubMedGoogle Scholar
• WHO. Immunization, vaccines and biologicals. Pertussis 2013 global figures. Available at www.who.int/immunization/monitoring_surveillance/Burden/vpd
   Google Scholar
• Available at http://www.cdc.gov/pertussis/surv-reporting/cases-by-year.htm.
   Google Scholar
• Rota MC, Ausiello CM, D'Amelio R, et al. Prevalence of markers of exposure to Bordetella pertussis among Italian young adults. Clin Infect Dis. 1998;26:297–302.
   PubMed Web of Science ®Google Scholar
• Smith W. The complement-fixation reaction in influenza. Lancet 1936;2:1256–1259.
   Google Scholar
• Chenoweth A, Waltz AD, Stokes Jr J, et al. Active immunization with the viruses of human and swine influenza. Am J Dis Children 1936;52:757–758.
   Google Scholar
• Francis T Jr, Magil TP. The antibody response of human subjects vaccinated with the virus of human influenza. J Exp Med 1937;65:251–259.
   PubMedGoogle Scholar
• Salk JE, Lavin GI, Francis T. The antigenic potency of epidemic influenza virus following inactivation by ultraviolet radiation. J Exp Med 1940;72:729–745.
   PubMedGoogle Scholar
• Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011;12:786–779.
   PubMed Web of Science ®Google Scholar
• Phillips CJ, Woolpert T, Sevick C, et al. Comparison of the effectiveness of trivalent inactivated influenza vaccine and live, attenuated influenza vaccine in preventing influenza-like illness among US military service members, 2006–2009. Clin Infect Dis. 2013;56:11–19.
   PubMed Web of Science ®Google Scholar
• Lee YT, Kim KH, Ko EJ, et al. New vaccines against influenza virus. Clin Exp Vaccine Res. 2014;3:12–28.
   PubMedGoogle Scholar
• Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011;204:845–853.
   PubMed Web of Science ®Google Scholar
• Lu Y, Welsh JP, Swartz JR. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci USA. 2014;111:125–130.
   PubMed Web of Science ®Google Scholar
• Weller TH, Robbins FC, Enders JF. Cultivation of poliomyelitis virus in cultures of human foreskin and embryonic tissues. Proc Soc Exp Biol Med 1949;72:153–155.
   PubMed Web of Science ®Google Scholar
• Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 2000;18:1436–1447.
   PubMed Web of Science ®Google Scholar
• Yun SI, Lee YM. Japanese encephalitis: the virus and vaccines. Hum Vaccin Immunother. 2014;10:263–267.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. Poliomyelitis. Atkinson W, Wolfe S, Hamborsky J, McIntyre L, editors, 11th ed. Washington DC: Public Health Foundation; 2015; pp. 297–310.
   Google Scholar
• Howe HA, Bodian D. Poliomyelitis in the chimpanzee: a clinical pathological study. Bull Johns Hopk Hosp 1941;69:149–181.
   Google Scholar
• Bodian D, Morgan IM, Howe HA. Differentiation of types of poliomyelitis viruses; the grouping of fourteen strains into three basic immunologic types. Am J Hyg 1949;49:234–245.
   PubMed Web of Science ®Google Scholar
• Melnick JL, Horstmann DM. Active immunity to poliomyelitis in chimpanzees following subclinical infection. J Exp Med 1947;85:287–303.
   PubMed Web of Science ®Google Scholar
• von Magnus H, Melnick JL. Antibody response in monkeys following oral administration of poliomyelitis virus. J Immunol 1948;60:583–596.
   PubMed Web of Science ®Google Scholar
• Bodian D, Horstman DM. Polioviruses. In: Horsfall FL, Tamm I, editors, Viral and Rickettsial Infection of Man, 4th ed, Philadelphia: Lippincott; 1965, p. 430–473.
   Google Scholar
• Salk JE. Poliomyelitis vaccine preparation and administration; analysis of basic premises and current practices. JAMA 1959;169:1829–1838.
   PubMed Web of Science ®Google Scholar
• Monto AS. Francis field trial of inactivated poliomyelitis vaccine: background and lessons for today. Epidemiol Rev 1999;21:7–23.
   PubMed Web of Science ®Google Scholar
• Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992;14:568–579.
   PubMed Web of Science ®Google Scholar
• Baicus A. History of polio vaccination. World J Virol 2012;1:108–114.
   PubMedGoogle Scholar
• Koprowski HL, Jervis GA, Norton TW. Immune responses in human volunteers upon oral administration of a rodent-adapted strain of poliomyelitis. Am J Hyg 1952;55:108–1126.
   PubMed Web of Science ®Google Scholar
• Melnick J, Plotkin S. Oral polio vaccine and the results of its use. In: Stanley Plotkin, editor. History of vaccine development. New York: Springer; 2011. p. 170.
   Google Scholar
• Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, et al. Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA 1960;173:1521–1526.
   PubMed Web of Science ®Google Scholar
• Mundel T, Orenstein WA. No country is safe without global eradication of poliomyelitis. N Engl J Med 2013;369:2045–2046.
   PubMed Web of Science ®Google Scholar
• Hoke CH Jr, Snyder CE Jr. History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system. Vaccine. 2013;31:1623–1632.
   PubMed Web of Science ®Google Scholar
• Enders JF, Katz SL, Milovanovic MV, et al. Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: techniques for assay of effects of vaccination. N Engl J Med 1960;263:153–159.
   PubMed Web of Science ®Google Scholar
• Buynak EB, Hilleman MR. Live attenuated mumps virus vaccine 1. Vaccine development. Proc Soc Exp Biol Med 1966;123:768–775.
   PubMed Web of Science ®Google Scholar
• Hilleman MR, Buynak EB, Weibel RE, et al. Current concepts: live attenuated rubella-virus vaccine. New Engl J Med 1968;279:300–303.
   PubMed Web of Science ®Google Scholar
• D'Amelio R, Biselli R, Fascia G, et al. Measles-mumps-rubella vaccine in the Italian armed forces. JAMA 2000;284:2059.
   PubMed Web of Science ®Google Scholar
• Lista F, Faggioni G, Peragallo MS, et al. Molecular analysis of early postvaccine mumps-like disease in Italian military recruits. JAMA 2002;287:1114–1115.
   PubMed Web of Science ®Google Scholar
• Anon. Global control and regional elimination of measles, 2010–2011. MMWR 2013;62:27–31.
   PubMed Web of Science ®Google Scholar
• Loucq C. Vaccines today, vaccines tomorrow: a perspective. Clin Exp Vaccine Res 2013;2:4–7.
   PubMedGoogle Scholar
• Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637–641.
   PubMed Web of Science ®Google Scholar
• Retraction–Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 2010;375:445.
   PubMed Web of Science ®Google Scholar
• Blumberg BS, Alter H. A “new” antigen in leukemia sera. JAMA 1965;191:101–106.
   Google Scholar
• Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci USA 1968;60:814–821.
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis B. Fact sheet N°204, updated March 2015. Available at www.who.int/mediacentre/ factsheets/fs204/en/
   Google Scholar
• Valenzuela P, Medina A, Rutter WJ, et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982;298:347–350.
   PubMed Web of Science ®Google Scholar
• McAleer WJ, Buynak EB, Maigetter RZ, et al. Human hepatitis B vaccine from recombinant yeast. Nature 1984;307:178–180.
   PubMed Web of Science ®Google Scholar
• Hilleman MR, Buynak EB, Roehm RR, et al. Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci 1975;270:401–404.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Pizza M, De Magistris MT, et al. Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin. Immunobiology 1992;184:230–239.
   PubMed Web of Science ®Google Scholar
• Sutton CE, Higgins S, Allen AC, et al. Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine. PLoS Pathog 2013;9:e1003264.
   PubMed Web of Science ®Google Scholar
• Poland GA. Vaccines against Lyme disease: What happened and what lessons can we learn? Clin Infect Dis. 2011;52(Suppl 3):s253–s258.
   PubMed Web of Science ®Google Scholar
• Müller M, Gissmann L. A long way: history of the prophylactic papillomavirus vaccine. Dis Markers. 2007;23:331–336.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:630–632.
   PubMedGoogle Scholar
• Zhou J, Sun XY, Stenzel DJ, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251–257.
   PubMed Web of Science ®Google Scholar
• Ghim SJ, Jenson AB, Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology 1992;190:548–552.
   PubMed Web of Science ®Google Scholar
• Rose RC, Bonnez W, Reichman RC, et al. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol. 1993;67:1936–1944.
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol. 1993;67:6929–6936.
   PubMed Web of Science ®Google Scholar
• Plotkin S. History of vaccination. Proc Natl Acad Sci USA 2014;111:12283–12287.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, et al. Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–723.
   PubMed Web of Science ®Google Scholar
• Parashar UM, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565–571.
   PubMed Web of Science ®Google Scholar
• Ward RL, Bernstein DI, Smith VE, et al. Rotavirus immunoglobulin A responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. J Infect Dis 2004;189:2290–2293.
   PubMed Web of Science ®Google Scholar
• Pneumococcal conjugate vaccine for childhood immunization—WHO position paper. Wkly Epidemiol Rec 2007;82:93–104.
   PubMedGoogle Scholar
• Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89–12. Vaccine 1998;16:381–387.
   PubMed Web of Science ®Google Scholar
• Clark HF, Offit PA. Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann 2004;33:536–543.
   PubMed Web of Science ®Google Scholar
• Clark HF, Offit PA, Ellis RW, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis. 1996;174(Suppl 1):S73–S80.
   PubMed Web of Science ®Google Scholar
• Clark HF, Offit PA, Plotkin SA, et al. The new pentavalent rotavirus vaccine composed of bovine (strain WC3)-human rotavirus reassortants. Pediatr Infect Dis J. 2006;25:577–583.
   PubMed Web of Science ®Google Scholar
• Patel MM, López-Collada VR, Bulhões MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011;364:2283–2292.
   PubMed Web of Science ®Google Scholar
• Yih WK, Lieu TA, Kulldorff M, et al. Intussusception Risk after Rotavirus Vaccination in U.S. Infants. N Engl J Med 2014;370: 503–512.
   PubMed Web of Science ®Google Scholar
• Weintraub ES, Baggs J, Duffy J, et al. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med. 2014;370:513–519.
   PubMed Web of Science ®Google Scholar
• Glass RI, Parashar UD. Rotavirus vaccines–balancing intussusception risks and health benefits. N Engl J Med. 2014;370:568–570.
   PubMed Web of Science ®Google Scholar
• Germanier R, Füer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis 1975;131:553–558.
   PubMed Web of Science ®Google Scholar
• Ivanoff B, Levine MM. Typhoid fever: continuing challenges from a resilient bacterial foe. Bull Inst Pasteur 1997;95:129–142.
   Google Scholar
• Tarr PE, Kuppens L, Jones TC, et al. Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: potential use in an epidemic in Tajikistan. Am J Trop Med Hyg 1999;61:163–170.
   PubMed Web of Science ®Google Scholar
• D'Amelio R, Tagliabue A, Nencioni L, et al. Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. Infect Immun 1988;56:2731–2735.
   PubMed Web of Science ®Google Scholar
• WHO. Cholera vaccines. WHO position paper. Weekly Epidemiological Record 2010;85: 117–128.
   PubMedGoogle Scholar
• Takahashi M. Development and characterization of a live varicella vaccine (Oka strain). Biken J. 1984;27:31–36.
   PubMedGoogle Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults” (PDF). N Engl J Med 2005;352:2271–2284.
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ. Shingles Prevention Study Group. Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis 2008;197(Suppl 2):S228–S236.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–296.
   PubMed Web of Science ®Google Scholar
• Steffen R. Immunization against hepatitis A and hepatitis B infections. J Travel Med 2001;8(Suppl 1):S9–S16.
   PubMedGoogle Scholar
• Hicks DJ, Fooks AR, Johnson N. Developments in rabies vaccines. Clin Exp Immunol 2012;169:199–204.
   PubMed Web of Science ®Google Scholar
• Macleod CM, Hodges RG, Heidelberger M, et al. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med. 1945;82:445–465.
   Web of Science ®Google Scholar
• Robbins JB, Parke JC Jr, Schneerson R, et al. Quantitative measurement of “natural” and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res. 1973;7:103–110.
   PubMed Web of Science ®Google Scholar
• Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969;129:1367–1384.
   PubMed Web of Science ®Google Scholar
• Wong KH, Feeley JC, Northrup RS, et al. Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals. Infect Immun. 1974;9:348–353.
   PubMed Web of Science ®Google Scholar
• Le Moli S, Matricardi PM, Quinti I, et al. Clonotypic analysis of human antibodies specific for Neisseria meningitidis polysaccharides A and C in adults. Clin Exp Immunol 1991;83:460–465.
   PubMed Web of Science ®Google Scholar
• Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med. 2005;11(4 Suppl):S54–S62.
   PubMed Web of Science ®Google Scholar
• Avery OT, Goebel WF. Chemical-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med 1929; 50: 533–542.
   PubMedGoogle Scholar
• Jennings H. Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease. J Infect Dis. 1992;165(Suppl 1):S156–S159.
   PubMed Web of Science ®Google Scholar
• Tai JY, Vella PP, McLean AA, et al. Haemophilus influenzae type b polysaccharide-protein conjugate vaccine. Proc Soc Exp Biol Med. 1987;184:154–161.
   PubMed Web of Science ®Google Scholar
• Schneerson R, Barrera O, Sutton A, et al. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide–protein conjugates. J Exp Med 1980;152:361–376.
   PubMed Web of Science ®Google Scholar
• Fairley CK, Begg N, Borrow R, et al. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996;174:1360–1363.
   PubMed Web of Science ®Google Scholar
• Schneerson R. Robbins JB, Park JC Jr, et al. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun 1986;52:519–528.
   PubMed Web of Science ®Google Scholar
• Szu, SC, Stone AL, Robbins JD, et al. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. J. Exp. Med 1987;166:1510–1524.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009;9:213–220.
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012;205:1408–1416.
   PubMed Web of Science ®Google Scholar
• Clarke ET, Williams NA, Findlow J, et al. Polysaccharide-Specific memory B cells generated by conjugate vaccines in humans conform to the CD27+IgG+ isotype-switched memory B cell phenotype and require contact-dependent signals from bystander T cells activated by bacterial proteins to differentiate into plasma cells. J Immunol 2013;191:6071–6083.
   PubMed Web of Science ®Google Scholar
• Poolman JT, Peeters CC, van den Dobbelsteen GP. The history of pneumococcal conjugate vaccine development: dose selection. Expert Rev Vaccines 2013;12:1379–1394.
   PubMed Web of Science ®Google Scholar
• Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011;23:407–413.
   PubMed Web of Science ®Google Scholar
• Moffitt KL, Yadav P, Weinberger DM, et al. Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine. 2012;30:4316–4322.
   PubMed Web of Science ®Google Scholar
• CDC. Biological and chemical terrorism: strategic plan for preparedness and response, recommendations of the CDC Strategic Planning Workgroup 2000. MMWR Morb Mortal Wkly Rep 2000;49(RR-4):1–14.
   PubMedGoogle Scholar
• Jernigan DB, Raghunathan PL, Bell BP, et al. National Anthrax Epidemiologic Investigation Team. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002;8:1019–1028.
   PubMed Web of Science ®Google Scholar
• Reed DS, Smith LP, Cole KS, et al. Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain. Infect Immun. 2014;82:2098–2105.
   PubMed Web of Science ®Google Scholar
• Rueckert C, Guzmán CA. Vaccines: from empirical development to rational design. PLoS Pathog 2012;8:e1003001.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Six revolutions in vaccinology. Pediatr Infect Dis J 2005;24:1–9.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Minireview. Vaccines: the fourth century. 2009;16:1709–1719.
   Google Scholar
• Neumann G, Watanabe T, Ito H, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 1999;96:9345–9350.
   PubMed Web of Science ®Google Scholar
• Mora M, Veggi D, Santini L, et al. Reverse vaccinology. Drug Discov Today 2003;8:459–464.
   PubMed Web of Science ®Google Scholar
• Moriel DG, Scarselli M, Serino L, et al. Genome-based vaccine development: a short cut for the future. Hum Vaccin. 2008;4:184–188.
   PubMed Web of Science ®Google Scholar
• Kelly DF, Rappuoli R. Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Adv Exp Med Biol 2005;568:217–223.
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103:10834–10839.
   PubMed Web of Science ®Google Scholar
• Flingai S, Czerwonko M, Goodman J, et al. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 2013;4:354.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity 2010;33:516–529.
   PubMed Web of Science ®Google Scholar
• Nakaya HI, Li S, Pulendran B. Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med. 2012;4:193–205.
   PubMed Web of Science ®Google Scholar
• Lessons from vaccine history. Nat Med 2012;18:1717.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988;239:476–481.
   PubMed Web of Science ®Google Scholar
• Villar L, Dayan GH, Arredondo-García JL et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372:113–123.
   PubMed Web of Science ®Google Scholar
• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013;496:504–507.
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis C. Fact sheet N°164, updated April 2014. Available at www.who.int/mediacentre/ factsheets/fs164/en/
   Google Scholar
• Cox AL, Thomas DL. Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis 2013;57(S2):S46–S50.
   PubMed Web of Science ®Google Scholar
• WHO, Fact sheet N°280, updated June 2014. Available at www.who.int/mediacentre/factsheets/ fs280/en/
   Google Scholar
• Zhang J, Zhang XF, Huang SJ, et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med. 2015;372:914–922.
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191:654–665.
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194:1661–1671.
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881–1893.
   PubMed Web of Science ®Google Scholar
• Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010;5:357–361.
   PubMed Web of Science ®Google Scholar
• Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11:507–515.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–2220.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275–1286.
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011;477:466–470.
   PubMed Web of Science ®Google Scholar
• Burton DR, Poignard P, Stanfield RL, et al. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012;337:183–186.
   PubMed Web of Science ®Google Scholar
• Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol. 2013;31:705–742.
   PubMed Web of Science ®Google Scholar
• Nabel GJ. Designing Tomorrow's vaccines. N Engl J Med 2013;368:551–560.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhou T, Zhu J, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011;333:1593–1602.
   PubMed Web of Science ®Google Scholar
• Dimitrov DS. Therapeutic antibodies, vaccines and antibodyomes. mAbs 2010;2:347–356.
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol 1969;89:422–434.
   PubMed Web of Science ®Google Scholar
• Dudas RA, Karron RA. Respiratory Syncytial Virus Vaccines. Clin Microbiol Rev 1998;11:430–439.
   PubMed Web of Science ®Google Scholar
• Gomez RS, Guisle-Marsollier I, Bohmwald K, et al. Respiratory Syncytial Virus: pathology, therapeutic drugs and prophylaxis. Immunol Lett. 2014;162(1 Pt A):237–247.
   PubMed Web of Science ®Google Scholar
• Kabanova A, Perez L, Lilleri D, et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci U S A. 2014;111:17965–17970.
   PubMed Web of Science ®Google Scholar
• Worgall S. 40 years on: have we finally got a vaccine for Pseudomonas aeruginosa? Future Microbiol. 2012;7:1333–1335.
   PubMed Web of Science ®Google Scholar
• Bagnoli F, Fontana MR, Soldaini E, et al. Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proc Natl Acad Sci U S A.2015;112:3680–3685.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:1005–1070.
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365:1863–1875.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. The Lancet 2015;[Epub ahead of print]:pii:S0140-6736(15)61117-5.
   Google Scholar
• WHO. Ebola vaccines, therapies and diagnostics. Questions and answers.2015. Last update 27 May 2015. Available at www.who.int/medicines/emp_ebola_q_as/en/
   Google Scholar
• Rebeaud F, Bachmann MF. Immunization strategies for Clostridium difficile infections. Expert Rev Vaccines. 2012;11:469–479.
   PubMed Web of Science ®Google Scholar
• Spencer J, Leuzzi R, Buckley A, et al. Vaccination against Clostridium difficile using toxin fragments: observations and analysis in animal models. Gut Microbes. 2014;5:225–232.
   PubMed Web of Science ®Google Scholar
• Ramon G. Procédés pour accroitre la production des Antitoxines. Ann Inst Pasteur 1926;40: 1–10.
   Google Scholar
• Kuroda E, Coban C, Ishii KJ. Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. Int Rev Immunol 2013;32:209–220.
   PubMed Web of Science ®Google Scholar
• Hogenesch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol 2013;3:406.
   PubMed Web of Science ®Google Scholar
• Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine. 2012;30:2256–2272.
   PubMed Web of Science ®Google Scholar
• Tagliabue A, Rappuoli R. Vaccine adjuvants. The dream become real. Human Vaccines 2008;4:347–349.
   PubMed Web of Science ®Google Scholar
• Khurana S, Chearwae W, Castellino F, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010;2:15ra5.
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011;3:85ra48.
   PubMed Web of Science ®Google Scholar
• Tsai TF. MF59 adjuvanted seasonal and pandemic influenza vaccines. Yakuga Zasshi 2011;131:1733–1741.
   PubMed Web of Science ®Google Scholar
• Milanetti F, Germano V, Nisini R, et al. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009–10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol 2014; 177:287–294.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013;346:f794.
   PubMed Web of Science ®Google Scholar
• Tsai T, Del Giudice G, Crucitti A, et al. Is the adjuvant solely to blame? BMJ. 2013;346:f2375.
   PubMed Web of Science ®Google Scholar
• Masoudi S, Ploen D, Kunz K, et al. The adjuvant component α-tocopherol triggers via modulation of Nrf2 the expression and turnover of hypocretin in vitro and its implication to the development of narcolepsy. Vaccine. 2014;32:2980–2988.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Orenstein WA, Offit PA. Vaccines. 5th Edition. Philadelphia: Saunders, Elsevier; 2008.
   Google Scholar
• Calabro S, Tortoli M, Baudner BC, et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011;29:1812–1823.
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt-and TLR4 agonist- based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009;183:6186–6197.
   PubMed Web of Science ®Google Scholar
• Glück R, Mischler R, Brantschen S, et al. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 1992;90:2491–2495.
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant system AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011;29:2461–2473.
   PubMed Web of Science ®Google Scholar
• Moser C, Muller M, Kaeser MD, et al. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines 2013;12:779–791.
   PubMed Web of Science ®Google Scholar
• Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114.
   PubMed Web of Science ®Google Scholar
• Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw. 2015;15:51–57.
   PubMed Web of Science ®Google Scholar
• Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011;12:786–795.
   PubMed Web of Science ®Google Scholar
• MMWR. Global routine vaccination coverage. 2013.2014;63:1055–1058.
   Google Scholar
• Steffen R, Connor BA. Vaccines in travel health: from risk assessment to priorities. J Travel Med 2005;12:26–35.
   PubMed Web of Science ®Google Scholar
• D'Amelio R, Heymann DL. Can the military contribute to global surveillance and control of infectious diseases? Emerg Infect Dis 1998;4:704–705.
   PubMed Web of Science ®Google Scholar
• Grabenstein JD, Pittman PR, Greenwood JT, et al. Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol Rev 2006;28:3–26.
   PubMed Web of Science ®Google Scholar
• Bozzo P, Narducci A, Einarson A. Vaccination during pregnancy. Can Fam Physician 2011; 57:555–557.
   PubMed Web of Science ®Google Scholar
• Sydnor E, Perl TM. Healthcare providers as sources of vaccine-preventable diseases. Vaccine. 2014;32:4814–4822.
   PubMed Web of Science ®Google Scholar
• Fortunato F, Tafuri S, Cozza V, et al. Low vaccination coverage among Italian healthcare workers in 2013. Hum Vaccin Immunother. 2015;11:133–139.
   PubMed Web of Science ®Google Scholar
• Thompson CN, Kama M, Acharya S, et al. Typhoid fever in Fiji: a reversible plague? Trop Med Int Health. 2014;19:1284–1292.
   PubMed Web of Science ®Google Scholar
• Yu MI, Lee SD, Lu RH, et al. Need for vaccination of susceptible food handlers against hepatitis A in Taiwan. Zhonghua Yi Xue Za Zhi (Taipei). 2000;63:798–803.
   Google Scholar
• Germano V, Cattaruzza MS, Osborn J, et al. Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists. J Transl Med 2014;12:77.
   PubMed Web of Science ®Google Scholar
• Salemi S, D'Amelio R. Are anti-infectious vaccination safe and effective in patients with autoimmunity? Int Rev Immunol 2010;29:270–314.
   PubMed Web of Science ®Google Scholar
• Hmamouchi I, Winthrop K, Launay O, et al. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: Data from the international COMORA cohort. Vaccine. 2015;33:1446–1452.
   PubMed Web of Science ®Google Scholar
• van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414–422.
   PubMed Web of Science ®Google Scholar
• Dougados M. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 2015;33:1446–1452.
   PubMed Web of Science ®Google Scholar
• Biondo MI, Germano V, Pietrosanti M, et al. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor α agents therapy in antibody to hepatitis B core antigen positive/ hepatitis B surface antigen negative subjects with chronic inflammatory arthropathies. Eur J Intern Med. 2014;25:482–484.
   PubMed Web of Science ®Google Scholar
• Ferreira I, Isenberg D. Vaccines and biologics. Ann Rheum Dis. 2014;73:1446–1454.
   PubMed Web of Science ®Google Scholar
• Weinberger B, Grubeck-Loebenstein B. Vaccines for the elderly. Clin Microbiol Infect 2012;18(Suppl 5):100–108.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Biological and chemical terrorism: strategic plan for preparedness and response, recommendations of the CDC Strategic Planning Workgroup 2000. MMWR Morb Mortal Wkly Rep 2000;49(RR-4):1–14.
   PubMedGoogle Scholar
• Ehreth J. The global value of vaccination. Vaccine 2003;21:596–600.
   PubMed Web of Science ®Google Scholar
• Zenteno-Cuevas R. Update on the Development of TB vaccines. Curr Pharm Biotechnol. 2013; 14:940–946.
   PubMed Web of Science ®Google Scholar
• Frey SE, Winokur PL, Salata RA, et al. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. Vaccine 2013; 31:3025–3033.
   PubMed Web of Science ®Google Scholar
• Oyston PC, Williamson ED. Prophylaxis and therapy of plague. Expert Rev Anti Infect Ther 2013;11:817–829.
   PubMed Web of Science ®Google Scholar
• Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 2013;31:3502–3518.
   PubMed Web of Science ®Google Scholar
• Yauch LE, Shresta S. Dengue virus vaccine development. Adv Virus Res 2014;88:315–372.
   PubMed Web of Science ®Google Scholar
• Yang K, Varga SM. Mucosal vaccines against respiratory syncytial virus. Curr Opin Virol 2014; 6:78–84.
   Web of Science ®Google Scholar
• Wang D, Fu TM. Progress on human cytomegalovirus vaccines for prevention of congenital infection and disease. Curr Opin Virol 2014;6C:13–23.
   Web of Science ®Google Scholar
• Shedlock DJ, Aviles J, Talbott KT, et al. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther. 2013;21:1432–1444.
   PubMed Web of Science ®Google Scholar
• Low N, Bavdekar A, Jeyaseelan L, et al. A randomized, controlled trial of an aerosolized vaccine against measles. N Engl J Med 2015;372:1519–1529.
   PubMed Web of Science ®Google Scholar
• Offit P. Back to the future. Expert Rev Vaccines 2004;3:107–108.
   PubMedGoogle Scholar
• Yang YT, Silverman RD. Social distancing and the unvaccinated. N Engl J Med 2015;372:1481–1483.
   PubMed Web of Science ®Google Scholar